Arginine and Linear Growth in Children and Adolescents: Scientific Evidence or Marketing Claim?
| Author | Babak Elyasi | en |
| Orcid | Babak Elyasi [0009-0008-3308-8949] | en |
| Issued Date | 2026-11-30 | en |
| Abstract | Context: Arginine is a conditionally essential amino acid involved in nitrogen metabolism, protein synthesis, nitric oxide production, and several metabolic pathways. It has also been used intravenously as a pharmacological stimulus in growth hormone (GH) stimulation testing. These physiological effects have led to widespread claims that oral arginine supplementation can increase linear growth in children and adolescents. However, an acute hormonal response should not be equated with a clinically meaningful increase in height. Evidence Acquisition: This narrative review examines the biological fate of arginine after administration and its relationship to GH secretion and growth plate physiology; it also examines evidence concerning insulin-like growth factor-1 (IGF-1) and clinical studies evaluating oral arginine supplementation and linear growth. Major pediatric and endocrine textbooks, international clinical guidelines, and recent systematic reviews and meta-analyses were considered, with particular attention to evidence directly evaluating growth outcomes rather than surrogate hormonal responses. Results: Arginine can acutely increase GH secretion, partly by attenuating somatostatin-mediated inhibition. However, this response is transient and differs substantially from sustained activation of the GH–IGF-1 axis and persistent stimulation of the growth plate. A 2023 systematic review and meta-analysis found no significant overall effect of arginine supplementation on IGF-1 concentrations. A 2026 systematic review and meta-analysis of oral arginine in prepubertal children with idiopathic short stature reported a small increase in height velocity in pooled analyses that included 6- or 12-month interventions, corresponding to a re-expressed mean difference of approximately 0.59 cm/year (95% CI: 0.19 – 1.00). However, the evidence was considered low quality, and the effect was not statistically significant when the analysis was restricted to 12-month interventions. Conclusions: Current evidence does not establish oral arginine as a standard treatment for increasing height in children and adolescents. The distinction between an acute GH response, a biological effect on the GH–IGF-1 axis, increased growth velocity, and an increase in adult height is essential when evaluating claims concerning arginine supplementation. In children with short stature, assessment of growth pattern, growth velocity, familial target height, pubertal status, nutritional status, and possible underlying disease should precede consideration of supplements. Further adequately powered randomized controlled trials with standardized growth outcomes and sufficiently long follow-up are needed. | en |
| DOI | https://doi.org/10.5812/jcp-175161 | en |
| URI | https://brieflands.com/journals/jcp/articles/175161 | en |
| Keyword | Arginine | en |
| Keyword | Growth and Development | en |
| Keyword | Growth Hormone | en |
| Keyword | Insulin-Like Growth Factor I | en |
| Keyword | Body Height | en |
| Keyword | Child | en |
| Keyword | Adolescent | en |
| Keyword | Growth Plate | en |
| Publisher | Brieflands | en |
| Title | Arginine and Linear Growth in Children and Adolescents: Scientific Evidence or Marketing Claim? | en |
| Type | Review Article | en |